Literature DB >> 21396776

Motor cortex stimulation reduces hyperalgesia in an animal model of central pain.

Jessica M Lucas1, Yadong Ji, Radi Masri.   

Abstract

Electrical stimulation of the primary motor cortex has been used since 1991 to treat chronic neuropathic pain. Since its inception, motor cortex stimulation (MCS) treatment has had varied clinical outcomes. Until this point, there has not been a systematic study of the stimulation parameters that most effectively treat chronic pain, or of the mechanisms by which MCS relieves pain. Here, using a rodent model of central pain, we perform a systematic study of stimulation parameters used for MCS and investigate the mechanisms by which MCS reduces hyperalgesia. Specifically, we study the role of the inhibitory nucleus zona incerta (ZI) in mediating the analgesic effects of MCS. In animals with mechanical and thermal hyperalgesia, we find that stimulation at 50 μA, 50 Hz, and 300 μs square pulses for 30 minutes is sufficient to reverse mechanical and thermal hyperalgesia. We also find that stimulation of the ZI mimics the effects of MCS and that reversible inactivation of ZI blocks the effects of MCS. These findings suggest that the reduction of hyperalgesia may be due to MCS effects on ZI. In an animal model of central pain syndrome, motor cortex stimulation reduces hyperalgesia by activating zona incerta and therefore restoring inhibition in the thalamus.
Copyright © 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21396776      PMCID: PMC3098950          DOI: 10.1016/j.pain.2011.02.025

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  35 in total

1.  Role of microglia and astrocyte in central pain syndrome following electrolytic lesion at the spinothalamic tract in rats.

Authors:  Kobra Naseri; Elham Saghaei; Fatemeh Abbaszadeh; Mina Afhami; Ali Haeri; Farzaneh Rahimi; Masoumeh Jorjani
Journal:  J Mol Neurosci       Date:  2012-06-22       Impact factor: 3.444

2.  Application of optogenetics-mediated motor cortex stimulation in the treatment of chronic neuropathic pain.

Authors:  Sufang Liu; Feng Tao
Journal:  J Transl Sci       Date:  2016-07-11

3.  Activation of the Intrinsic Pain Inhibitory Circuit from the Midcingulate Cg2 to Zona Incerta Alleviates Neuropathic Pain.

Authors:  Ting-Ting Hu; Ran-Ran Wang; Yu Du; Fang Guo; Yu-Xing Wu; Yi Wang; Shuang Wang; Xiang-Yao Li; Shi-Hong Zhang; Zhong Chen
Journal:  J Neurosci       Date:  2019-10-11       Impact factor: 6.167

4.  Top-Down Cortical Control of Acute and Chronic Pain.

Authors:  Louise Urien; Jing Wang
Journal:  Psychosom Med       Date:  2019 Nov/Dec       Impact factor: 4.312

5.  Post-translational modification of cortical GluA receptors in rodents following spinal cord lesion.

Authors:  L Jiang; P Voulalas; Y Ji; R Masri
Journal:  Neuroscience       Date:  2015-12-24       Impact factor: 3.590

6.  Motor cortex stimulation suppresses cortical responses to noxious hindpaw stimulation after spinal cord lesion in rats.

Authors:  Li Jiang; Yadong Ji; Pamela J Voulalas; Michael Keaser; Su Xu; Rao P Gullapalli; Joel Greenspan; Radi Masri
Journal:  Brain Stimul       Date:  2013-12-27       Impact factor: 8.955

7.  Pathological activity in mediodorsal thalamus of rats with spinal cord injury pain.

Authors:  Jessica L Whitt; Radi Masri; Nisha S Pulimood; Asaf Keller
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

Review 8.  Cortical reorganization after spinal cord injury: always for good?

Authors:  K A Moxon; A Oliviero; J Aguilar; G Foffani
Journal:  Neuroscience       Date:  2014-07-02       Impact factor: 3.590

9.  Motor cortex stimulation activates the incertothalamic pathway in an animal model of spinal cord injury.

Authors:  Myeounghoon Cha; Yadong Ji; Radi Masri
Journal:  J Pain       Date:  2013-01-16       Impact factor: 5.820

10.  Chronic pain following spinal cord injury.

Authors:  Radi Masri; Asaf Keller
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.